FOLFOX4/XELOX in stage II–III colon cancer: Early survival data of the Italian three or six colon adjuvant (TOSCA) trial

Roberto Labianca, Claudia Mucciarini, Paolo Bidoli, Domenico Corsi, Vincenzo Montesarchio, Maria Bochicchio Anna, Vincenzo Iaffaioli, Andrea Ciarlo, Sabino De Placido, Domenico Amoroso, Enrico Cortesi, Bruno Daniele, Dino Amadori, Daniele Turci, Silvia Pelliccioni, Saverio Cinieri, Alberto Ravaioli, Elena Piazza, Eliana Rulli, Alberto Sobrero

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)iii147
JournalAnnals of Oncology
Volume28
DOIs
Publication statusPublished - Jun 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Labianca, R., Mucciarini, C., Bidoli, P., Corsi, D., Montesarchio, V., Bochicchio Anna, M., Iaffaioli, V., Ciarlo, A., De Placido, S., Amoroso, D., Cortesi, E., Daniele, B., Amadori, D., Turci, D., Pelliccioni, S., Cinieri, S., Ravaioli, A., Piazza, E., Rulli, E., & Sobrero, A. (2017). FOLFOX4/XELOX in stage II–III colon cancer: Early survival data of the Italian three or six colon adjuvant (TOSCA) trial. Annals of Oncology, 28, iii147. https://doi.org/10.1093/annonc/mdx262.024